Abstract B41: Targeting androgen-independent prostate cancer through epigenetic reprogramming

Conclusions: There is no approved drug that can specifically target AR- independent NEPC tumors. The restricted set of therapeutic options against this subtype of prostate cancer and consequent dismal outcome stem in part from our incomplete understanding of the molecular events underlying its pathogenesis. The discovery that epigenetics can be a key process in distinguishing tumors that are AR-independent and at high risk for NEPC progression represents an important step to highlight the use of epigenetic modifiers as therapeutic agents for this subtype of prostate cancer.Citation Format: Loredana Puca, Dong Gao, Myriam Kossai, Joanna Cyrta, Clarisse Marotz, Juan Miguel Mosquera, Theresa Y. MacDonald, Andrea Sboner, Rema Rao, Yu Chen, Mark A. Rubin, Himisha Beltran. Targeting androgen-independent prostate cancer through epigenetic reprogramming. [abstract]. In: Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer; Sep 24-27, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2016;76(2 Suppl):Abstract nr B41.

Source: Cancer Research - January 14, 2016 Category: Cancer & Oncology Authors: Puca, L., Gao, D., Kossai, M., Cyrta, J., Marotz, C., Mosquera, J. M., MacDonald, T. Y., Sboner, A., Rao, R., Chen, Y., Rubin, M. A., Beltran, H. Tags: Epigenetic Cancer Therapies Source Type: research